AI Article Synopsis
- Novel therapeutic approaches are required for rhabdomyosarcoma (RMS), a common soft-tissue cancer in children, highlighting the need for new treatment options.
- Researchers identified B7-H3 as a key regulatory protein predominantly found in RMS tumors, absent in normal tissues, making it a potential treatment target.
- The study suggests that targeting B7-H3 might enhance T-cell responses against RMS tumors, offering insights for developing innovative immunotherapies.
Article Abstract
Novel therapeutic strategies are needed for the treatment of rhabdomyosarcoma (RMS), the most common soft-tissue sarcoma in children. By using a combination of cell surface proteomics and transcriptomic profiling of RMS and normal muscle, we generated a catalog of targetable cell surface proteins enriched in RMS tumors. Among the top candidates, we identified B7-H3 as the major immunoregulatory molecule expressed by RMS tumors. By using a large cohort of tissue specimens, we demonstrated that B7-H3 is expressed in a majority of RMS tumors while not detected in normal human tissues. Through a deconvolution analysis of the RMS tumor RNA-seq data, we showed that B7-H3-rich tumors are enriched in macrophages M1, NK cells, and depleted in CD8-T cells. Furthermore, in vitro functional assays showed that B7-H3 knockout in RMS tumor cells increases T-cell mediated cytotoxicity. Altogether, our study uncovers new potential targets for the treatment of RMS and provides the first biological insights into the role of B7-H3 in RMS biology, paving the way for the development of next-generation immunotherapies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8466404 | PMC |
| http://dx.doi.org/10.3390/cancers13184528 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary perianal alveolar rhabdomyosarcoma with uncommon metastatic sites: a case report and follow-up using F-FDG PET/CT.
Front Med (Lausanne)
December 2024
Department of Nuclear Medicine, Peking University First Hospital, Beijing, China.
Article Synopsis
- Rhabdomyosarcoma (RMS) is a rare and aggressive pediatric cancer that commonly affects children and adolescents, with alveolar rhabdomyosarcoma (ARMS) often developing in areas like the trunk and head/neck.
- An 11-year-old girl diagnosed with ARMS presented with a perianal mass, showing aggressive metastasis to the pleura, lymph nodes, and even bones, which is less common.
- The case underscores the difficulties in diagnosing and treating ARMS, stressing the importance of early detection, advanced imaging techniques, and the need for ongoing research to develop better treatment options.
Editorial: Advances in artificial intelligence and machine learning applications for the imaging of bone and soft tissue tumors.
Front Radiol
December 2024
Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, CA, United States.
Lymphadenectomy in the treatment of sarcomas - indications and technique.
Oncol Rev
December 2024
Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
Sarcomas are a rare type of malignancy with limited treatment options so far. This analysis aimed to describe the impact of lymphadenectomy on treating sarcoma patients. Sarcomas characterized by lymphatic spread are rare.
View Article and Find Full Text PDFPrognostic role of bone erosion in orbital RMS: a report from the European Pediatric Soft Tissue Sarcoma Study Group (EpSSG).
Front Oncol
December 2024
Department of Women's and Children's Health, University of Padova, Padova, Italy.
Background: Orbital rhabdomyosarcoma (RMS) is often limited to the orbital cavity and has a favorable prognosis. In some cases, the tumor can erode the orbital bone and behave as a parameningeal RMS (PM-RMS); thus, it is treated more intensively. However, the current protocols do not provide any guidance on how to consider different grades of bone erosion (BE) that can vary widely, hampering a uniform classification and the subsequent treatment assignment.
View Article and Find Full Text PDFCytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas.
Front Immunol
December 2024
Department of Pediatrics, Children's Cancer Research Center, Kinderklinik München Schwabing, TUM School of Medicine, Technical University of Munich, Munich, Germany.
Introduction: Pediatric sarcomas, including osteosarcoma (OS), Ewing sarcoma (EwS) and rhabdomyosarcoma (RMS) carry low somatic mutational burden and low MHC-I expression, posing a challenge for T cell therapies. Our previous study showed that mediators of monocyte maturation sensitized the EwS cell line A673 to lysis by HLA-A*02:01/CHM1-specific allorestricted T cell receptor (TCR) transgenic CD8 T cells (CHM1 CD8 T cells).
Methods: In this study, we tested a panel of monocyte maturation cytokines for their ability to upregulate immunogenic cell surface markers on OS, EwS and RMS cell lines, using flow cytometry.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!